AI assistant
ARVINAS, INC. — Director's Dealing 2018
Sep 26, 2018
32625_dirs_2018-09-26_06b48cd1-fb71-4ab3-9c97-7ff1a93b309b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ARVINAS HOLDING COMPANY, LLC (ARVN)
CIK: 0001655759
Period of Report: 2018-09-26
Reporting Person: Houston John G (Director, President and CEO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 742860 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series C Preferred Stock | $ | Common Stock (12484) | Direct |
Footnotes
F1: 497,342 of such shares are subject to monthly vesting, 27,029 of such shares will vest upon achievement of a regulatory milestone for the Issuer's androgen receptor program and 27,029 of such shares will vest upon achievement of a regulatory milestone for the Issuer's estrogen receptor program.
F2: The Series C Preferred Stock is convertible into Common Stock on a 3.25-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.